ArticleAmerican journal of respiratory cell and molecular biology2012
LPS-stimulated cytokine production in type I cells is modulated by the renin-angiotensin system.
Article in American journal of respiratory cell and molecular biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Pooled it
- CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies.Nature communications · 2022Trial
- Immunology of Sepsis.Clinics in chest medicine · 2026Review
- The Role of Macrophages and Alveolar Epithelial Cells in the Development of ARDS.Inflammation · 2023Review
- Cellular and Molecular Mechanisms in Idiopathic Pulmonary Fibrosis.Advances in respiratory medicine · 2023Review
- Azilsartan inhibits inflammation-triggered bone resorption and osteoclastogenesisFrontiers in endocrinology · 2023Article
- Optimal Management of Heart Failure and Chronic Obstructive Pulmonary Disease: Clinical Challenges.International journal of general medicine · 2022Review
- Angiotensin-Converting Enzyme 2 (ACE2) in the Context of Respiratory Diseases and Its Importance in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The actin-regulatory protein Hem-1 is essential for alveolar macrophage development.The Journal of experimental medicine · 2021Article
- Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Role of endothelial microRNA 155 on capillary leakage in systemic inflammation.Critical care (London, England) · 2021Article
- Severe COVID-19 Lung Infection in Older People and Periodontitis.Journal of clinical medicine · 2021Review
- An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19.Frontiers in medicine · 2021Article
- GM-CSF: Orchestrating the Pulmonary Response to Infection.Frontiers in pharmacology · 2021Review
- Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic.Frontiers in physiology · 2021Review
- Drug repurposing and cytokine management in response to COVID-19: A review.International immunopharmacology · 2020Review
- ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives.Frontiers in molecular biosciences · 2020Review
- Cell fate analysis in fetal mouse lung reveals distinct pathways for TI and TII cell development.American journal of physiology. Lung cellular and molecular physiology · 2019Article
- Alveolar-Capillary Membrane-Related Pulmonary Cells as a Target in Endotoxin-Induced Acute Lung Injury.International journal of molecular sciences · 2019Review
- Influence of the interaction between Ac‑SDKP and Ang II on the pathogenesis and development of silicotic fibrosis.Molecular medicine reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The alveolar epithelium serves as a barrier to the entry of potential respiratory pathogens. Alveolar Type II (TII) cells have immunomodulatory functions, but whether Type I (TI) cells, which comprise approximately 95% of the alveolar epithelium, also play a role in immunity is unknown. Because the renin-angiotensin system (RAS) is emerging as an important mediator of inflammation, and angiotensin-converting enzyme 2 (ACE2), an element of the RAS, has been implicated in lung injury, we hypothesize that TI cells can produce cytokines in response to LPS stimulation, and that this inflammation can be modulated by the RAS. Alveolar TI cells were isolated from adult Sprague-Dawley rat lungs that had been injured with an intratracheal instillation of LPS. PCR was performed to determine whether TI cells expressed transcripts for TNF-α, IL-6, or IL-1β at baseline and after lung injury. Immunocytochemical and protein analysis detected angiotensin II (Ang II) and ACE2, as well as angiotensin Type 1 receptor (AT1R) and Type 2 receptor (AT2R), in TI cells. To separate cell-specific responses, primary TI cells were isolated, cultured, and exposed to LPS, Ang II, or specific inhibitors of AT1R or AT2R. Cytokine production was assayed by ELISA. LPS stimulated the production of all cytokines, whereas ACE2 and losartan, an AT1R inhibitor, blocked elements of the LPS-induced cytokine response. Primary TI cells produce cytokines when treated with LPS, contain important components of the RAS, and can modulate LPS-induced cytokine production via the RAS, suggesting a role for TI cells in the innate immune response of the lung.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.